Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…
Asia-Pacific The latest pharma news from the Asia-Pacific region, including upcoming IPOs for Prestige Biopharma and HH&L Acquisition; logistics challenges for COVID-19 vaccine distributors; and Moderna’s CMO-based vaccine manufacturing strategy in Asia. Singapore-based Prestige Biopharma prepares for IPO on the Korea Exchange https://www.businesstimes.com.sg/garage/prestige-biopharma-eyes-at-least-18t-won-valuation-in-korean-ipo SINGAPORE-BASED Prestige Biopharma expects an implied market…
Rankings Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural mechanism which is present in living cells that selectively “turns off” specific gene’s expressions, thereby affecting the production of a specific protein that contributes to disease.…
See our Cookie Privacy Policy Here